ArticleNPJ precision oncology2025
Machine learning-driven comprehensive profiling of tumor heterogeneity and sialylation in hepatocellular carcinoma.
Article in NPJ precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- POTEF upregulation drives hepatocellular carcinoma progression via oncogenic signaling and immune modulation.Scientific reports · 2026Article
- Integrating innovative multiomics and machine learning strategies for prognostic biomarker discovery in hepatocellular carcinoma: guiding personalized treatment strategies with single-cell analysis.Translational cancer research · 2026Article
- Article
- Joint latent profiles of death anxiety and treatment adherence in HCC patients.Frontiers in psychiatry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) exhibits profound cellular heterogeneity, the understanding of which is critical for improving prognosis and therapy. Using single-cell RNA sequencing of 32,247 cells from human HCC samples, we characterized the tumor ecosystem and identified five malignant hepatocyte subpopulations with distinct molecular profiles and stage-specific enrichment. Among these, the S100A6⁺ C1 and S100A9⁺ C4 subpopulations were predominantly associated with advanced tumors and actively remodeled the tumor microenvironment through enhanced signaling pathways such as MDK and MIF. We further identified PGAM2 as a key transcriptional regulator in early-stage tumors, whose activity correlated with sialylation-a process linked to immune evasion. Based on these findings, we developed a prognostic model integrating PGAM2 and sialylation-related genes, which robustly stratified patients into high- and low-risk groups with significantly different survival outcomes, immune contextures, and predicted therapeutic responses. Functional experiments validated AGRN, a component of the signature, as a functional driver of HCC proliferation and invasion. Collectively, our results decode the cellular and molecular heterogeneity of HCC, provide a clinically relevant prognostic tool, and highlight potential targets for further investigation.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.